We have some exciting news to share! The Motley Fool UK has now become The Twelfth Magpie -- an independent, UK-owned company, led by our long-serving UK management team — Mark Rogers, Chris Nials and Heather Adlington. In practical terms, it’s the same team you know, now fully focused on serving our UK readers and members.

Just as importantly, our approach remains unchanged: long-term, jargon-free, and on your side. This site is our new home, and there will be extra tweaks made across the coming few days as we settle in. So if anything looks a little off, please bear with us!

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Are AstraZeneca plc & Thomas Cook Group plc ‘Screaming Buys’?

Should you buy AstraZeneca plc (LON: AZN) and Thomas Cook Group plc (LON: TCG) right now?

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

In the long run, all companies encounter highly challenging periods. They can be due to external factors such as a weakening in demand for a particular product or a slowdown in the wider economy. They can also be caused by internal challenges, such as poor planning and a strategy which ultimately leads to disappointing top and bottom line performance.

Either way, it normally has a very negative impact on a company’s share price and, while the effects can be horrific for investors, it also presents a very appealing buying opportunity. That’s because if the company can either adopt a better strategy or the external factors improve, capital gains could prove to be very enticing.

XXX

One company which has endured a very tough period is AstraZeneca (LSE: AZN). Its problems have largely been its own making, with the company failing to develop sufficient new drugs and put in place a suitable pipeline to overcome the inevitable loss of patents on key, blockbuster drugs. Furthermore, it also failed to use its cash in the most efficient manner; favouring a share buyback programme ahead of investing in research and development capabilities.

The result has been a severe decline in profitability, with AstraZeneca’s earnings per share expected to be just 62% of their 2011 level when the company reports its 2015 full-year results. However, AstraZeneca appears to now be making all of the right moves through which to mount a successful comeback, with an ambitious acquisition programme breathing new life into the company’s pipeline.

Clearly, it will inevitably take time to post positive profit growth. However, it seems likely to do so over the medium term which makes it current price to earnings (P/E) ratio of 16.1 seem hugely appealing.

Similarly, Thomas Cook (LSE: TCG) has also endured a troubled past, with the company becoming a loss-making entity in the period 2011 to 2014. This had a disastrous impact on the company’s share price, with it falling to a low of 13p in 2012 and there being major concerns about whether it would survive its difficult trading period.

However, now that the economic outlook is improved Thomas Cook is moving from strength to strength. Today’s results show that the company has made its first annual profit in five years despite the negative impact on demand for its holidays caused by the terrorist incidents of recent months. And, with the winter season already being 58% sold, it appears to be well-placed to deliver continued strong performance moving forward.

Looking ahead, Thomas Cook is forecast to increase its earnings by 28% next year which, alongside a P/E ratio of 9.4, puts it on a price to earnings growth (PEG) ratio of just 0.3. This indicates that its shares have very appealing capital gains prospects – especially since the UK and European economies are showing signs of life and are set to benefit from a continued loose monetary policy in future years.

Peter Stephens owns shares of AstraZeneca. The Motley Fool UK has recommended AstraZeneca. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Friends and sisters exploring the outdoors together in Cornwall. They are standing with their arms around each other at the coast.
Investing Articles

£503 buys 14 shares in this FTSE 250 stock that returned 23.9% annually for the last 15 years

This FTSE 250 stock has averaged a huge return for 15 years. At today's price, £503 buys 14 shares. But…

Read more »

Black woman using loudspeaker to be heard
Investing Articles

£1,000 buys 25 shares in this FTSE 100 stock that’s returned 29.2% annually for the last 10 years

This FTSE 100 mining stock has returned close to 30% a year for a decade. At 3,995p, £1,000 buys 25…

Read more »

Female student sitting at the steps and using laptop
Investing Articles

Down 47%, is this growth stock finally worth buying in May?

With a £288m order book and a hidden pipeline of defence and nuclear contracts, is this growth stock now too…

Read more »

House models and one with REIT - standing for real estate investment trust - written on it.
Investing Articles

2 REITs yielding 7%+ to consider for passive income in 2026

A REIT backed by the NHS and another backed by Tesco and Sainsbury's with both yielding 7%+. Here's why I'm…

Read more »

Woman riding her old fashioned bicycle along the Beach Esplanade at Aberdeen, Scotland.
Investing Articles

Just 97 shares of this UK dividend stock generate £238 in passive income

A 5.7% yield, £238 in passive income from just 97 shares, and one of the most divisive dividend stocks on…

Read more »

ISA coins
Investing Articles

£10,000 in an ISA generates a second income of…

The London Stock Exchange is home to some of the world's most generous dividends. But how big a second income…

Read more »

Shot of a senior man drinking coffee and looking thoughtfully out of a window
Investing Articles

Expert recommendations: 2 top income stocks yielding 7%+!

With yields of 7.2% and 7.8% respectively, these two income stocks are catching the eyes of institutional analysts. Should investors…

Read more »

Illustration of flames over a black background
Investing Articles

3 top income-focused stocks to buy in May 2026, according to experts

Looking for a stock to buy for income in May 2026? Experts have flagged these three UK dividend shares as…

Read more »